Windlas Biotech Limited has informed the Exchange about Investor Presentation
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported its 10th consecutive quarter of record revenue, with Q1 FY26 revenue of Rs 210 Cr, up 20% year-on-year. EBITDA grew 27% to Rs 27 Cr and PAT rose 31% to Rs 18 Cr, while EPS stood at Rs 8.4, a 30% jump. Gross margin expanded by 71 basis points to 38.3% and EBITDA margin improved by 70 basis points to 12.6%, with growth driven across all three verticals: CDMO (Rs 160 Cr, +18%), Trade Generics & Institutional (Rs 44 Cr, +25%), and Exports (Rs 6 Cr, +45%). The company also paid a dividend of Rs 12.2 Cr (Rs 5.8 per share) for FY25 and remains net debt-free with Rs 213 Cr in liquidity. The company has a 5-year CAGR of 18% in revenue, 23% in EBITDA, and 30% in PAT.
Strong, broad-based quarterly performance with expanding margins and a debt-free balance sheet signals healthy operational momentum, likely to be viewed positively by investors. The consistent track record of 10 straight quarters of record revenue reinforces confidence in the company's growth trajectory.